SWOG S0910: A Phase 2 Trial of Clofarabine/Cytarabine/Epratuzumab for Relapsed/Refractory Acute Lymphocytic Leukaemia

Precursor B-acute lymphoblastic leukaemias (pre-B ALLs) comprise the majority of ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell surface. In the present study (Southwestern Oncology Group S0910), we evaluated the addition of epratuzumab, a humanized monoclonal antibody ag...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Advani, Anjali S., McDonough, Shannon, Coutre, Steven, Wood, Brent, Radich, Jerald, Mims, Martha, O’Donnell, Margaret, Elkins, Stephanie, Becker, Michael, Othus, Megan, Appelbaum, Frederick R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4209396/
https://ncbi.nlm.nih.gov/pubmed/24579885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12778
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia